VIVUS — Obesity Week Preconference Session 2013
26 slides from VIVUS's conference presentation, Nov 12, 2013
Slide 1: Obesity Week Preconference Session
OBESITY WEEK Preconference Session ©2013 VIVUS Inc. All rights reserved | www.vivus.com November 12, 2013 Barbara Troupin, MD, MBA VP, Scientific Communication & Risk Management
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT ©2013 VIVUS Inc. All rights reserved | www.vivus.com 1 Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "ant
Slide 3: Qsymia Prescribing Information
QSYMIA PRESCRIBING INFORMATION About Qsymia Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (ove
Slide 4: EQUIP: Significant Weight Loss Occurred Early and Was Sustained
EQUIP: SIGNIFICANT WEIGHT LOSS OCCURRED EARLY AND WAS SUSTAINED (SEVERELY OBESE PATIENTS) P<.0001 for both doses vs placebo, and 15 mg/92 mg vs 3.75 mg/23 mg at all time points for both completers and ITT-LOCF. LS=least-squares. EWL=excess weight loss, Excess weight is defined as the weight in exces
Slide 5: CONQUER: Significant Weight Loss Was Sustained
ITT-LOCF CONQUER: SIGNIFICANT WEIGHT LOSS WAS SUSTAINED (PATIENTS WITH MULTIPLE COMORBIDITIES) P<.0001 for both doses vs placebo, and 15 mg/92 mg vs 7.5 mg/46 mg at all time points for both completers and ITT-LOCF. 1. Qsymia [prescribing information]. Mountain View, CA: VIVUS, Inc.; 2013. 2. Data on
Slide 6: Qsymia: Improvement in Risk Factors
QSYMIA: IMPROVEMENT IN RISK FACTORS Diastolic BP Systolic BP Fibrinogen Triglycerides TChol:HDL IWQOL total Fasting glucose HOMA-IR Fasting insulin HbA1c hs-CRP ALT Apnea Hypopnea Index Placebo subtracted effect size Placebo subtracted effect size Favors Qsymia Favors Placebo Favors Qsymia Favors Pl
Slide 7: SEQUEL: Weight Loss Sustained Over Two Years
SEQUEL: WEIGHT LOSS SUSTAINED OVER TWO YEARS *p<0.0001 vs placebo. Garvey WT et al. Am J Clin Nutr. 2012 ITT-LOCF Completers & ITT-LOCF -10.8% -38.4% -41.5% Completers EWL 108 108 -1.8% -9.3%* -10.5%* -9.3%* -10.7%* -2.2% 6 - 16 - 14 - 12 - 10 - 8 - 6 - 4 - 2 0 Percent Weight Loss (LS Mean) Week Pla
Slide 8: Commonly Reported Adverse Events and AEs Leading to Discontinuation
Please consult complete adverse event tables available in the full Prescribing Information for Qsymia. Qsymia [prescribing information]. Mountain View, CA: VIVUS, Inc.; 2013. Most Common Adverse Events, % Paraesthesia 1.9 4.2 13.7 19.9 Dry mouth 2.8 6.7 13.5 19.1 Constipation 6.1 7.9 15.1 16.1 Dysge
Slide 9: Obesity Market Evolution
OBESITY MARKET EVOLUTION 8
Slide 10: New AACE Treatment Algorithm: Medical Therapy Now Recommended
NEW AACE TREATMENT ALGORITHM (MAY-2013): MEDICAL THERAPY IS NOW RECOMMENDED 9 Obesity management and FDA-approved anti-obesity medications now recommended for: Prediabetes Diabetes Dyslipidemia Hypertension 1st ever inclusion of drug therapy in treatment algorithm Primary Care Physicians refer to AA
Slide 11: Greater Recognition of Obesity as a Disease
GREATER RECOGNITION OF OBESITY AS A DISEASE Jun-2013 - For the first time, obesity is recognized as a disease by the leading medical association in the U.S. AMA recognition is important support for policy makers, healthcare providers and payers 10
Slide 12: Treat and Reduce Obesity Act of 2013
TREAT AND REDUCE OBESITY ACT OF 2013 Introduced into House and Senate Jun-2013 Among other provisions, the Act would remove the Medicare Part D exclusion of obesity medications Bi-partisan support Senators Carper (D-DE), Murkowski (R-AK) Representatives Cassidy (R-LA), Kind (D-WI) 11
Slide 13: Qsymia Recent Highlights
QSYMIA RECENT HIGHLIGHTS 12
Slide 14: Qsymia Educationally-Focused REMS
QSYMIA EDUCATIONALLY-FOCUSED REMS Goal: to inform prescribers and female patients of reproductive potential regarding: the increased risk of congenital malformations, specifically orofacial clefts, in infants exposed to Qsymia during the first trimester of pregnancy, the importance of pregnancy prev
Slide 15: Qsymia Retail Roll-out Success
QSYMIA RETAIL ROLL-OUT SUCCESS Certified Retail Pharmacy Status (31-Oct-2013) >31,000 pharmacies now certified to dispense Qsymia Chains include: A&P, Albertsons, Costco, CVS, Kmart, Kroger, Publix, Rite Aid, Safeway, Walgreens/Duane Reade, Walmart, Wegmans, Winn-Dixie, many others Prescriber and pa
Slide 16: Qsymia Retail Pharmacy Availability Created a Step-Up in Demand in 3Q2013
# Prescribers # TRxs Launch thru Sep-2013 ~29,000 ~280,000 Added in 3Q2013 ~8,000 ~109,000 Source: Vivus Data on file- 10/4/2013 file. * Estimates pending finalization and reversals % Growth 97% 37% 35% QSYMIA RETAIL PHARMACY AVAILABILITY CREATED A STEP-UP IN DEMAND IN 3Q2013 15
Slide 17: Qsymia Reimbursement Continues to Improve
QSYMIA REIMBURSEMENT CONTINUES TO IMPROVE As of 30-Sep-2013, ~38% of U.S. Commercial Lives have access to Qsymia at Tier 3 or better, up from <20% at approval 16 Qsymia Access: % of U.S. Commercial Lives
Slide 18: Recent Publication Reports Impact of Qsymia on Type 2 Diabetes
RECENT PUBLICATION REPORTS IMPACT OF QSYMIA ON TYPE 2 DIABETES “Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended-Release” W. Timothy Garvey, MD, et al. Diabetes Care (epub Oct 8, 2013) Patients on the Recommended (7.5/
Slide 19: SEQUEL: Incidence Rates of Type 2 Diabetes Reduced Over 108 Weeks
SEQUEL: INCIDENCE RATES OF TYPE 2 DIABETES REDUCED WITH QSYMIA OVER 108 WEEKS 18 The annualized incidence rate of type 2 diabetes was reduced with Qsymia by 70.5-78.7 % compared to placebo/lifestyle Prediabetes and/or Metabolic Syndrome Population Garvey WT, et al. Diabetes Care. 2013. [epub ahead o
Slide 20: Qsymia Experience on Market
QSYMIA EXPERIENCE ON MARKET 19
Slide 21: Drug Utilization Study OB-303 (CONQUER)
DRUG UTILIZATION STUDY OB-303 (CONQUER) Age (years) 51 BMI, kg/m2 37 Female, % 70 Hypertension Hx, % 53 Dyslipidemia Hx, % 36 Diabetes Hx, % 16 Hx=history 20
Slide 22: Drug Utilization Study OB-303 (CONQUER)
DRUG UTILIZATION STUDY OB-303 (CONQUER) Drug Utilization Study Age (years) 51 49 BMI, kg/m2 37 37 Female, % 70 78 Hypertension Hx, % 53 42 Dyslipidemia Hx, % 36 50 Diabetes Hx, % 16 19 Hx=history. Data from first 10 months on market, reported in July 2013 70% of patients are aged 18-54 years old Sou
Slide 23: Qsymia Prescribers & Prescriptions by Specialty
Source: Vivus Data on file – launch-to-date (through 30-Sep-2013) QSYMIA PRESCRIBERS & PRESCRIPTIONS BY SPECIALTY 22
Slide 24: Qsymia Post-Marketing Experience
Most Commonly Reported Spontaneous AEs (consistent w/US Package Insert and clinical trials data) Paraesthesia Headache Dizziness Dry Mouth Insomnia ~90% of patients are on the recommended dose (7.5/46) QSYMIA POST-MARKETING EXPERIENCE 23 Source: Vivus Data on file – 10-25-2013
Slide 25: Qsymia Summary
QSYMIA SUMMARY Qsymia was approved by FDA in Jul-2012; launched Sep-2012 First and only medication that provides sustained, best-in-class weight loss efficacy in excess of 10% Clinically relevant improvements in multiple cardiometabolic and other risk factors Well tolerated; known risks are appropri
Slide 26: Summary
SUMMARY Obesity treatment landscape evolving Treatment being used in appropriate patient population Access and coverage slowly but steadily improving This market is starting to build, and will only benefit from additional new entrants and investment 25